title: [Osteoporosis].
abstract: FRAX is a useful device to select patients with high fracture risk. Glucocorticoid induced osteoporosis, mainly due to a decrease of bone formation, is well controlled with teriparatide treatment and shows an effect of zoledronate on bone mineral density greater than risedronate. Weekly and monthly risedronate have the same bone effects. Ibandronate prevents bone loss related to the use of anti-aromatase. Side effects associated with the bisphosphonates treatment such as osteonecrosis of the jaw, auricular fibrillation and subtrochanteric fractures are discussed. Tibolone prevents fractures. Denosumab reduces the risk of vertebral, non-vertebral and hip fractures. Calcium supplementation is not associated with an increased risk of cardiovascular events.
authors.affiliation: Service des maladies osseuses, Centre collaborateur de l'OMS pour la prevention de l'ostéoporose, Département de réhabilitation et gériatrie, HUG et Faculté de médecine, 1211 Genève 14. Brigitte.Uebelhart@hcuge.ch
authors.forename: Brigitte
authors.initials: B
authors.lastname: Uebelhart
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D050723:Fractures, Bone / Q000209:etiology*; D006801:Humans; D010024:Osteoporosis / Q000150:complications*; D018570:Risk Assessment; D014584:User-Computer Interface
chemical_list: D000305:Adrenal Cortex Hormones